

Please type a plus sign (+) inside this box →



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/775,517	
	Filing Date	February 2, 2002	
	First Named Inventor	Grabowski, et al.	
	Group Art Unit	1651	
	Examiner Name	Brett T. Ozga	
Total Number of Pages in This Submission	7	Attorney Docket Number	10872/0474345

RECEIVED
FEB 26 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/Declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Loy M. White Registration No. 43,262
Signature	
Date	January 24, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:			
Typed or printed name	Loy M. White		
Signature		Date	January 24, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY OF PAPER
ORIGINALLY FILED

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231
on January 24, 2002


Lois M. White
Name of Person Depositing Correspondence

Signature of Person Depositing Correspondence

1/B
PMT
2-28-02
RECEIVED

FEB 26 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Grabowski, et al

Application Serial No.:

09/775,517

Confirmation No.:

Filed:

February 2, 2001

Title:

LIPID HYDROLYSIS THERAPY FOR
ATHEROSCLEROSIS AND RELATED
DISEASES

Group Art Unit:

1651

Examiner:

Brett T. Ozga

Attorney/Agent Docket No.:

10872/0474345

RESPONSE UNDER 37 C.F.R. § 1.111

The Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This response to the non-final Office action dated October 30, 2001, is submitted in the above-identified application under 37 C.F.R. § 1.111. No fees are believed due at this time. Applicants respectfully request this response be considered by the Examiner under 37 C.F.R. § 1.112 and a timely Notice of Allowance be issued under 37 C.F.R. § 1.311 in this application.

AMENDMENTS

In the Claims

Please cancel Claim 52, 56 and 57 without prejudice.

Please amend Claim 51 to read as follows:

51. (Amended) A method for providing biologically active lipid hydrolyzing protein or polypeptide, or mixtures thereof, to cells of a mammal having deficiency in said biologically active lipid hydrolyzing protein or polypeptide, said method comprising administration into said cells a vector containing and expressing a DNA sequence

B1